ProBioGen Announces Innovent as a New Partner Signing License of GlymaxX® Technology

ProBioGen Announces Innovent as a New Partner Signing License of GlymaxX® Technology

BERLIN, Germany, January 11, 2022 / B3C newswire / -- ProBioGen today announced that Innovent Biologics, Inc. (1801.HK) has signed a multi-product license for ProBioGen's GlymaxX technology.

Under this license agreement, Innovent receives non-exclusive rights to use the afucosylation technology GlymaxX for multiple candidates in their pipeline. Therapeutic antibodies with low fucose content show a much higher antibody-dependent cellular cytotoxicity (ADCC) and therefore a higher killing activity against tumorigenic or infected cells. The therapeutic effect can therefore be greatly enhanced. GlymaxX technology is universally applicable, simple and effective and can be integrated into newly developed or already existing cell lines of different origins. In addition, this technology offers flexibility in terms of fucose level adjustment, since only one cell line is sufficient to be used to produce both fucosylated and afucosylated antibodies.

Dr. Gabriele Schneider, Chief Business Officer from ProBioGen stated: "We are very pleased to have Innovent as a new partner for a GlymaxX license. Since its foundation, Innovent has established itself in a very short time as an innovative biopharmaceutical company with its own fully-fledged antibody development platforms and a robust pipeline of antibodies. I am very much looking forward to this collaboration to benefit Innovent's products by the ease of use and high efficacy of our GlymaxX technology."